Advertisement

Topics

Targacept Company Profile

18:16 EDT 19th September 2018 | BioPortfolio

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder and resistant hypertension, attention deficit/hyperactivity disorder, Alzheimer’s disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.

Location

200 East First Street, Suite 300
Winston-Salem
North Carolina
27101-4165
United States of America

Contact

Phone: (336) 480-2100
Fax: (336) 480-2107
Email: jo.peay@targacept.com


News Articles [1 Associated News Articles listed on BioPortfolio]

PTV News: Dec 3, 2009

Top stories on December 3rd, 2009: AZ in billion dollar deal for Targacept's antidepressant Roche's diabetes drug "better than Merck's Januvia" Dyax shares skyrocket on FDA approval of Kalbitor ...

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers

Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression a...

An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DS...

Companies [4 Associated Companies listed on BioPortfolio]

Targacept, Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively m...

Targacept

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targ...

Targacept Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively m...

Targacept, Inc. and Catalyst Biosciences, Inc.

More Information about "Targacept" on BioPortfolio

We have published hundreds of Targacept news stories on BioPortfolio along with dozens of Targacept Clinical Trials and PubMed Articles about Targacept for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Targacept Companies in our database. You can also find out about relevant Targacept Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record